clinical trial · NCT04202835
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
McMaster University·phase2·active not recruiting·n = 80
Acute LeukemiaMyelodysplasiaChronic Graft-versus-host-diseaseCyclophosphamideAnti-Thymocyte globulin (rabbit)
brief summary
A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
started
Oct 14, 2020
primary completion
May 18, 2024
completion
Feb 7, 2026
last updated
May 11, 2025
detailed description
Patients with acute leukemia or myelodysplastic syndrome will be randomized to receive, or not receive, post transplant cyclophosphamide in addition to anti-thymocyte globulin.
official title
A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol